Implementation of a standardized protocol for prevention and management of oral mucositis in patients undergoing hematopoietic cell transplantation

Abstract

Purpose. Oral mucositis is a serious problem that affects a significant number of hematopoietic cell transplant (HCT) patients. There are many gaps in management, and evidence-based guidelines do not provide consistent recommendations. The purpose of this pilot study was to develop a mucositis oral care protocol for the prevention and management of mucositis in the HCT patient and to evaluate the clinical impact of its implementation.

Methods. After receipt of Institutional Review Board approval, all patients admitted to the Hematology—Oncology service for high-dose chemotherapy followed by an autologous or allogeneic HCT were eligible for the study. As part of a change in practice, a new mucositis protocol consisting of a specific oral care regimen was instituted for prevention and treatment of mucositis. Assessment of mucositis began upon admission to the hospital and the patient was evaluated using a mucositis grading scale on a daily basis by the physician and nursing staff. The new mucositis protocol was a part of the HCT service admission orders for each patient. The group of patients treated according to the new mucositis protocol were compared with a retrospective control group consisting of patients who had undergone management of oral mucositis under the previous standard of care. The primary endpoints were to evaluate incidence, severity, and duration of oral mucositis. Secondary endpoints included days requiring narcotics; days of parenteral nutrition, febrile neutropenia, antimicrobial therapy, and length of hospital stay.

Results. There were 13 patients enrolled in the control group and 12 patients in the new protocol group. The new protocol resulted in a decreased incidence (100% vs. 75%) and duration (19.2 vs. 8.3 days) of mucositis. Days of maximum grade one and three mucositis were decreased by 56%, and 70%, respectively. Days of maximum grade two mucositis, however increased by 22%. The days of narcotic use were reduced by 19% in the new protocol group (15.8 vs. 12.8 days). All patients in the new protocol group required parenteral nutrition, but days of use were reduced by 41% (17 vs. 10.2 days). The incidence of infection measured by days of febrile neutropenia and antimicrobial therapy were reduced by 35% (10.2 vs. 6.5 days) and 33% (17 vs. 11.4 days). Finally, the overall length of hospital stay was reduced by 7 days (30 vs. 23 days).

Conclusion. Implementation of a standardized oral care protocol for mucositis management resulted in a decreased incidence, duration and severity of mucositis, and also reduced the global negative impact of mucositis. Future studies may further evaluate the global impact by adjusting for confounding factors. J Oncol Pharm Practice (2010) 16: 195—204.

Keywords

mucositis oral care protocol bone marrow transplant

Get full access to this article

View all access options for this article.

References

Goldberg S. Patient perceptions about chemotherapy-induced oral mucositis: implications for primary/prophylaxis strategies. Support Care Cancer 2004; 12: 526-30.

Woo S. -B. A longitudinal study of oral ulcerative mucositis in bone marrow transplant patients. Cancer 1993; 72(5): 1612-17.

Lalla R. Treatment of mucositis, including new medications. Cancer 2006; 12: 348-54.

Rubenstein EB , Peterson DE , Schubert M. et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 2004 ; 100(9): 2026-46.

McGuire D. Barriers and strategies in implementation of oral care standards for cancer patients. Support Care Cancer 2003; 11: 435-41.

Sonis ST Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol 1998; 34(1): 39-43.

Ferretti GA , Ash RC , Brown RT et al. Control of oral mucositis and candidiasis in marrow transplantation: a prospective, double-blind trial of chlorhexidine digluconate oral rinse . Bone Marrow Transpl 1988; 3(5): 483-93.

Raether D. Effectiveness of oral chlorhexidine for reducing stomatitis in a pediatric bone marrow transplant population. Pediatr Dent 1989; 11(1): 37-42.

Ezzone S. Survey of oral hygiene regimens among bone marrow transplant centers . Oncol Nurs Forum 1993; 20(9): 1375-81.

10.

Beck S. Impact of a systematic oral care protocol on stomatitis after chemotherapy . Cancer Nurs 1979; 2(3): 185-99.

11.

Lorenz K.

Effect of two new chlorhexidine mouth rinses on the development of dental plaque, gingivitis and discoloration. A randomized, investigator-blind, placebo controlled 3 week experimental gingivitis study

J Clin Periodontol 2006; 33(8): 561-67.

12.

Papas AS , Clark RE , Martuscelli G. , O’Loughlin KT , Johansen E. , Miller KB A prospective, randomized trial for the prevention of mucositis in patients undergoing hematopooietic stem cell transplantation. Bone Marrow Transpl 2003; 31: 705-12.

13.

Potting CMJ. The effectiveness of commonly used mouthwashes for the prevention of chemotherapy-induced oral mucositis: a systematic review . Euro J Crit Care 2006; 15: 431-39.

14.

Palifermin (Kepivance®). Mayo Clinic Pharmacy and Therapeutics Committee Criteria for Use. Approved November 2005. Available at: http://mcjweb.mayo.edu/pt_committee/Documents/criteria%20for%20use/Palifermin%20cfu.pdf (accessed September 2008).

15.

Lilleby K. , Garcia P. , Gooley T. , McDonnnell P. , Taber R. , Holmberg L. et al. A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood cell transplantation. Bone Marrow transpl 2006; 37: 1031-35.

16.

Woo SB , Matin K. Off-site dental evaluation program for prospective bone marrow transplant recipients. J Am Dental Assoc 1997; 128: 189-93.

17.

Peterson D. Mouth pain and discomfort: All you need to know about mucositis, Cancer Care Connect, 2005 . Available at: http://www.cancercare.org. (accessed September 2008).

18.

National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 3. Available at: http://www.fda.gov/cder/cancer/toxicityframe.htm . (accessed September 4 2008).

19.

Caphosol Patient Administration guide. Available at: http://www.caphosol.com/assets/pdf/patients/CaphosolPatientInstructionSheet (accessed September 2008).

20.

Dodd M. Randomized clinical trial of the effectiveness of three commonly used mouthwashes to treat chemotherapy-induced mucositis. Oral Surg Oral Med Oral Pathol 2000; 90: 37-47.

21.

Spielberger R. et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004; 351: 2590-98.